Crovalimab + Eculizumab

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Trial Timeline

Sep 30, 2020 → Sep 30, 2027

NCT ID

NCT04432584

About Crovalimab + Eculizumab

Crovalimab + Eculizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is active. This product is registered under clinical trial identifier NCT04432584. Target conditions include Paroxysmal Nocturnal Hemoglobinuria.

What happened to similar drugs?

0 of 20 similar drugs in Paroxysmal Nocturnal Hemoglobinuria were approved

Approved (0) Terminated (4) Active (16)

🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄DanicopanAstraZenecaPhase 3

🔄Iptacopan (LNP023)NovartisPhase 3

🔄IptacopanNovartisPhase 3

🔄LNP023 + Eculizumab + RavulizumabNovartisPhase 3

🔄LNP023NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04434092	Phase 3	Active	Oct 8, 2020	Sep 30, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT04432584	Phase 3	Active	Sep 30, 2020	Sep 30, 2027	Paroxysmal Nocturnal Hemoglobinuria

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria

See all competitors

Product	Company	Stage	Hype Score
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	44
Crovalimab + Placebo	Chugai Pharmaceutical	Phase 1/2	36
Ravulizumab	AstraZeneca	Pre-clinical	30
Eculizumab	AstraZeneca	Phase 3	40
Danicopan	AstraZeneca	Phase 3	47
LNP023	Novartis	Pre-clinical	33
Iptacopan (LNP023)	Novartis	Phase 3	40
iptacopan	Novartis	Phase 2	35
LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Pre-clinical	30
Iptacopan	Novartis	Phase 3	40
LNP023 + Eculizumab + Ravulizumab	Novartis	Phase 3	40
LNP023	Novartis	Phase 3	47
LFG316 + LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	44
Crovalimab	Roche	Phase 3	44
ABP 959 + Eculizumab	Amgen	Phase 3	40
Pegcetacoplan	Swedish Orphan Biovitrum	Pre-clinical	33
BMS-919373 + Placebo (Matching with BMS-919373)	Bristol Myers Squibb	Phase 2	27
Humanized anti-Factor Bb monoclonal antibody + Placebo	Sanofi	Phase 1	29